Browsing Tag
Daniel Skovronsky
9 posts
Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal,…
August 18, 2024
Eli Lilly and Company announces first Lilly Gateway Labs facility in San Diego for 2024
In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE:…
November 29, 2023
Lilly to acquire gene therapy firm Akouos to discover hearing loss treatments
Lilly acquisition of Akouos : American pharmaceutical giant Eli Lilly and Company (Lilly) has agreed to acquire precision…
October 19, 2022
Lilly gets FDA EUA for bebtelovimab in mild-to-moderate Covid-19
Eli Lilly and Company (Lilly) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration…
February 12, 2022
Lilly begins real-world Covid-19 study of bamlanivimab in New Mexico to assess outcomes in high-risk patients
Eli Lilly begins a real-world Covid-19 study of bamlanivimab in New Mexico. Find out how mobile clinics aim to reduce hospitalizations in high-risk patients.
December 19, 2020
Lilly partners with UnitedHealth Group for pragmatic study of bamlanivimab in high-risk COVID-19 patients
Eli Lilly and Company (Lilly) has formed a strategic collaboration with UnitedHealth Group to conduct a pragmatic clinical…
December 6, 2020
FDA grants emergency use authorization for Bamlanivimab to treat Covid-19
The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for bamlanivimab (LY-CoV555), a neutralizing…
November 10, 2020
Lilly, Amgen collaborate to boost supply of potential COVID-19 therapies
Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the…
September 17, 2020
Lilly begins phase 1 coronavirus antibody trial with LY-CoV555
Coronavirus antibody trial : US pharma giant Eli Lilly and Company (Lilly) said that patients have been dosed…
June 1, 2020